Pierre Malchair
YOU?
Author Swipe
View article: Detection of previously undiagnosed or lost to follow-up hepatitis C infections by implementing an opportunistic screening in an emergency department
Detection of previously undiagnosed or lost to follow-up hepatitis C infections by implementing an opportunistic screening in an emergency department Open
Opportunistic screening in the ED significantly increased HCV testing and identified a higher prevalence of active infection compared to the general population. These findings support expanding screening guidelines to reach broader populat…
View article: Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant
Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant Open
We used the data from a successful therapeutic assay that used icatibant in patients with hypoxemic COVID-19 pneumonia (the ICAT·COVID trial) to explore pathophysiological mechanisms. We performed concurrent-type, criterion-related validit…
View article: Detection of previously undiagnosed or lost to follow-up hepatitis C infections by implementing an opportunistic screening in an emergency department
Detection of previously undiagnosed or lost to follow-up hepatitis C infections by implementing an opportunistic screening in an emergency department Open
View article: Study of initial natriuresis in patients with acute heart failure presenting to hospital emergency departments
Study of initial natriuresis in patients with acute heart failure presenting to hospital emergency departments Open
View article: Long-term analysis of the first fall and subsequent falls in the FALL-ER registry
Long-term analysis of the first fall and subsequent falls in the FALL-ER registry Open
View article: Assessing sepsis-induced immunosuppression to predict positive blood cultures
Assessing sepsis-induced immunosuppression to predict positive blood cultures Open
Introduction Bacteremia is a life-threatening condition that can progress to sepsis and septic shock, leading to significant mortality in the emergency department (ED). The standard diagnostic method, blood culture, is time-consuming and p…
View article: Author Correction: Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients
Author Correction: Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients Open
View article: Causes of death in patients with COVID-19: the HUBCOVID365 cohort findings
Causes of death in patients with COVID-19: the HUBCOVID365 cohort findings Open
OBJETIVOS. Describir, en pacientes con COVID-19, las diferentes causas de mortalidad, analizar las variables predictoras y si existen diferencias entre ellos. MATERIAL Y MÉTODO. Pacientes de la cohorte retrospectiva HUBCOVID365, diagnostic…
View article: The patient’s experience: a new view of the emergency department?
The patient’s experience: a new view of the emergency department? Open
View article: 4CPS-228 Impact and acceptance of pharmaceutical interventions for early medication reconciliation in the emergency department
4CPS-228 Impact and acceptance of pharmaceutical interventions for early medication reconciliation in the emergency department Open
Background and Importance Emergency departments (EDs) are characterised by high care load, staff rotation and critical situations that require rapid decisions. Early conciliation in high-risk patients may improve patient safety during care…
View article: Bayesian Analysis of the ICAT·COVID Randomized Clinical Trial
Bayesian Analysis of the ICAT·COVID Randomized Clinical Trial Open
This communication provides new effect measures in the multiplicative scale from the ICAT·COVID randomized clinical trial, obtained through Bayesian statistics. These could not be calculated using the traditional frequentist statistics inc…
View article: Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial
Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial Open
Background We aimed to evaluate icatibant, a competitive antagonist of the bradykinin B2 receptors, for the treatment of inpatients with coronavirus disease 2019 (COVID-19) pneumonia admitted in the early hypoxemic stage. Methods The rando…
View article: Análisis de la evolucion tras el alta de urgencias en pacientes con neumonía por COVID-19 en función del recurso sanitario utilizado para el seguimiento: estudio RESALSEVID
Análisis de la evolucion tras el alta de urgencias en pacientes con neumonía por COVID-19 en función del recurso sanitario utilizado para el seguimiento: estudio RESALSEVID Open
View article: Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients Open
View article: A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID)
A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID) Open
Background COVID-19 has quickly become a global pandemic with a substantial number of deaths and is a considerable burden for healthcare systems worldwide. Although most cases are paucisymptomatic and limited to the viral infection-related…
View article: High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial Open
View article: Convalescent plasma for outpatients with early COVID-19
Convalescent plasma for outpatients with early COVID-19 Open
Background Convalescent plasma (CP) for hospitalized patients with COVID-19 has not demonstrated clear benefits. However, data on outpatients with early symptoms are scarce. We aimed to assess whether treatment with CP administered during …
View article: A multicenter, open-label, randomized, proof-of-concept phase ii clinical trial to Assess the efficacy and safety of icatibant in patients infected with sars-cov-2 (covid-19) And admitted to hospital units without invasive mechanical ventilation. StudyProtocol (icat-covid)
A multicenter, open-label, randomized, proof-of-concept phase ii clinical trial to Assess the efficacy and safety of icatibant in patients infected with sars-cov-2 (covid-19) And admitted to hospital units without invasive mechanical ventilation. StudyProtocol (icat-covid) Open
Background: COVID-19 has quickly become a global pandemic with a substantial number of deaths and a substantial burden for healthcare systems worldwide. Although most cases are paucisymptomatic and limited to the viral infection related sy…
View article: Pulmonary Infections with Nontuberculous Mycobacteria, Catalonia, Spain, 1994–2014
Pulmonary Infections with Nontuberculous Mycobacteria, Catalonia, Spain, 1994–2014 Open
In Spain, systematic reporting of pulmonary infections with nontuberculous mycobacteria is not mandatory. Therefore, to determine trends, we retrospectively identified cases for January 1994-December 2014 in Catalonia. Over the 21 years, p…
View article: Hydroxychloroquine Myocardial Toxicity in a Patient with Systemic Lupus Erythematosus
Hydroxychloroquine Myocardial Toxicity in a Patient with Systemic Lupus Erythematosus Open
Hydroxychloroquine is an antimalarial drug used in many rheumatologic and systemic diseases. Although considered by clinicians to be relatively safe, serious side effects have been documented (retinotoxicity, neuromyotoxicity and cardiotox…